MEDANTANSEGlobal Health Limited· Healthcare ServicesHighNegative
Announced Wed, 4 Feb, 2026 · 16:20 IST

Q3 FY26 results, senior management and board changes announced

Promoter Family Board EntryManagement Changes View source PDFExplain this filing

MEDANTA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-0.9%Reaction day
₹1121.00
prior close
₹1090.00
announcement price
After-mkt
timing
Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)-0.3%-0.6% vs market
Hospital peers, median of 22sector-0.6%-0.3% vs sector

On the reaction day the stock moved 0.6 pts less than Nifty Midcap 150 and 0.3 pts less than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
+1.1
10m
+1.0
15m
+1.2
30m
+1.7
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-0.9-0.3-0.6-0.6-0.3
Next day
+1.9-0.3+2.2-0.7+2.6
2d
+3.5+1.2+2.3+1.7+1.8
3d
+1.2+1.6-0.4+2.0-0.8
4d
+2.6+1.6+0.9+5.5-2.9
5d
+2.5+1.1+1.4+6.2-3.7
1w
+2.1-0.1+2.2+4.5-2.5
15d
+3.8+0.4+3.4+6.4-2.6
1m
-0.8-3.1+2.3+3.2-4.0
2m
-7.7-8.7+1.0+3.2-10.9
3m
+4.5+0.8+3.7+9.3-4.8
UpDownMarket · Nifty Midcap 150Sector · Hospital peers, median of 22Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Global Health (Medanta) reported Q3 FY26 standalone revenue of Rs 9,402 mn (up 15.7% YoY) and PAT of Rs 799 mn (down 39% YoY). Consolidated revenue rose to Rs 11,210 mn; PAT was Rs 950 mn. PAT was hit by a Rs 352 mn one-time charge for new Labour Codes. Board appointed Mr. Malik Mohd. Ashhab as Head-Diagnostic Services, re-appointed two independent directors, and proposed appointing CMD Dr. Naresh Trehan's daughter Ms. Shonan Purie Trehan as non-executive director, subject to shareholder approval.

Likely market impact

Mixed Q3 with revenue growth but PAT dip from Labour Codes charge. Promoter family board addition may draw governance attention.